A recent article published in Nature Communications Medicine has reported the launch of a non-hormonal, reversible male contraceptive with 99% effectiveness in animal trials.

The drug YCT-529, which was tested in both mice and primates, inhibits the retinoic acid receptor alpha (RARα) protein, which blocks access to vitamin A, preventing sperm production and release. A lack of vitamin A causes infertility.

After oral administration to male mice, YCT-529 inhibited fertility within 4 weeks, which correlated with the disruption of spermatogenesis, demonstrating a specific inhibition of the RARα pathway. Within 6 weeks of discontinuing administration, the mice’s fertility was reversed.

Furthermore, YCT-529 inhibited sperm production in a non-human primate model within 2 weeks of oral administration, with no adverse side effects. Within 10–15 weeks of discontinuing administration, sperm counts in non-human primates were completely reversed.

Since it is a non-hormonal medication, it is expected not to present the side effects associated with hormone treatments in users. If infertility were achieved by suppressing testosterone, side effects related to the regulatory activity of this hormone would likely appear.

Preclinical studies showed that treatment with YTC-529 was effective, preventing pregnancies in mice in 99% of cases.

A Phase 1 human clinical trial is currently underway with 16 volunteer participants. It is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral doses of YCT-529.

Representative data on efficacy, safety and dose studies of this contraceptive treatment in humans will be available only after the completion of this and other similar studies and their subsequent research phases. This will determine its future commercialization.

The male contraceptive pill has been developed by researchers from Columbia University’s Department of Genetics and Development, YourChoice Therapeutics and the University of Minnesota’s Department of Medicinal Chemistry and Institute for Therapeutic Discovery and Development.

Bioethical assessment

The development of an effective, non-hormonal, well-tolerated, and highly effective male contraceptive could provide an alternative to current female hormonal treatments. These are formulated with hormones and have side effects, as we have previously reported.

In addition, since the new contraceptive is non-hormonal, it is expected to avoid the unwanted side effects associated with this type of treatment.

However, the optimism expressed by its promoters should be tempered given that retinoic acid receptor alpha (Rarα) blockade may present long-term side effects. These would be related to its antioxidant potential and cellular regulatory processes and could be inflammatory or hormonal.

Only studies with a larger number of participants than this first phase of the clinical trial and with longer follow-up periods will be able to determine the long-term safety level and its actual efficacy.

In this case, they would represent an advance over female hormonal contraceptives.

Since it inhibits spermiogenesis, its mechanism of action would be contraceptive, that is, it would prevent fertilization. It would not present bioethical difficulties regarding the possibility of anti-implantation mechanisms that cause embryo death.

Furthermore, the method is reversible, which would make it possible to recover the fertilizing capacity after the treatment is discontinued. This makes it preferable to surgical male sterilization by vasectomy, which is difficult to reverse.

In terms of ethical acceptability, women are freed from having to undergo contraceptive treatment and the possibility of embryonic loss is eliminated, but it entails the suppression of male fertility, resulting in reversible sterility.

This artificial intervention to render spermiogenesis inoperable also contributes to separating human sexuality from its reproductive potential, which presents difficulties of moral acceptability from the perspective of its natural condition.

Julio Tudela

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

Share This Story, Choose Your Platform!